Medical Devices & M&A
Medtronic Plans $650 Million Acquisition of SPR Therapeutics
What’s happening
Medtronic plans to buy SPR Therapeutics for about $650 million to expand its pain treatment technologies. SPR develops nerve stimulation therapies used to treat chronic pain without relying heavily on opioids.
What’s changing / Business impact
Increased investment in:
- non-opioid pain treatments
- nerve stimulation devices
- medical technology alternatives to painkillers
Expansion of device-based pain management.
Why this matters
The U.S. has struggled with a major opioid addiction crisis for years.
This shows healthcare companies are searching for alternatives to addictive pain medications, making medical devices increasingly critical in chronic pain treatment.